Abstract
Immunogenicity of 13-valent pneumococcal polysaccharide (PnPS) conjugate vaccine (PCV13) was evaluated in 38 rheumatoid arthritis patients under immunosuppressive treatment and 20 healthy controls (HC). Antibodies to all PnPS and diphtheria-toxin analogue conjugate protein were measured pre- (T0), 1 (T1), 6 (T2), 12 (T3) months post-immunization. Patients and HC had similar response to individual PnPS. Mean antibody levels to all PnPS but one doubled at T1 compared with T0, with T3 persistence for only 8-7/13 PnPS. Baseline antibody levels was inversely associated with the rate of responders at T1 (T1/T0≥2) to 11/13 PnPS. Few subjects reached protective IgG levels against some serotypes frequently isolated in Italian patients with invasive pneumococcal disease. Antibody response was not influenced by therapy, except the one to PS7F, which was reduced by tumor necrosis factor-α-inhibitors. Vaccination increased also anti-diphtheria IgG. Despite this study substantially confirmed the PCV13 immunogenicity in immunocompromised patients, it also revealed some limitations.
| Original language | English |
|---|---|
| Pages (from-to) | 18-27 |
| Number of pages | 10 |
| Journal | Clinical Immunology |
| Volume | 195 |
| DOIs | |
| Publication status | Published - Oct 1 2018 |
Fingerprint
Keywords
- 13-valent pneumococcal conjugate vaccine
- Antibody persistence
- Immunogenicity
- Immunosuppressive therapy
- Rheumatoid arthritis
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy. / Caporuscio, Sara; Ieraci, Roberto; Valesini, Guido; Teloni, Raffaela; Mariotti, Sabrina; Spinelli, Francesca Romana; Ferlito, Claudia; Salemi, Simonetta; Picchianti Diamanti, Andrea; Meneguzzi, Giorgia; Markovic, Milica; Sgrulletti, Mayla; von Hunolstein, Christina; Ralli, Luisa; Pinto, Antonietta; Salerno, Gerardo; Canzoni, Marco; Sorgi, Maria Laura; Laganà, Bruno; Di Rosa, Roberta; Nisini, Roberto; D'Amelio, Raffaele.
In: Clinical Immunology, Vol. 195, 01.10.2018, p. 18-27.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy
AU - Caporuscio, Sara
AU - Ieraci, Roberto
AU - Valesini, Guido
AU - Teloni, Raffaela
AU - Mariotti, Sabrina
AU - Spinelli, Francesca Romana
AU - Ferlito, Claudia
AU - Salemi, Simonetta
AU - Picchianti Diamanti, Andrea
AU - Meneguzzi, Giorgia
AU - Markovic, Milica
AU - Sgrulletti, Mayla
AU - von Hunolstein, Christina
AU - Ralli, Luisa
AU - Pinto, Antonietta
AU - Salerno, Gerardo
AU - Canzoni, Marco
AU - Sorgi, Maria Laura
AU - Laganà, Bruno
AU - Di Rosa, Roberta
AU - Nisini, Roberto
AU - D'Amelio, Raffaele
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Immunogenicity of 13-valent pneumococcal polysaccharide (PnPS) conjugate vaccine (PCV13) was evaluated in 38 rheumatoid arthritis patients under immunosuppressive treatment and 20 healthy controls (HC). Antibodies to all PnPS and diphtheria-toxin analogue conjugate protein were measured pre- (T0), 1 (T1), 6 (T2), 12 (T3) months post-immunization. Patients and HC had similar response to individual PnPS. Mean antibody levels to all PnPS but one doubled at T1 compared with T0, with T3 persistence for only 8-7/13 PnPS. Baseline antibody levels was inversely associated with the rate of responders at T1 (T1/T0≥2) to 11/13 PnPS. Few subjects reached protective IgG levels against some serotypes frequently isolated in Italian patients with invasive pneumococcal disease. Antibody response was not influenced by therapy, except the one to PS7F, which was reduced by tumor necrosis factor-α-inhibitors. Vaccination increased also anti-diphtheria IgG. Despite this study substantially confirmed the PCV13 immunogenicity in immunocompromised patients, it also revealed some limitations.
AB - Immunogenicity of 13-valent pneumococcal polysaccharide (PnPS) conjugate vaccine (PCV13) was evaluated in 38 rheumatoid arthritis patients under immunosuppressive treatment and 20 healthy controls (HC). Antibodies to all PnPS and diphtheria-toxin analogue conjugate protein were measured pre- (T0), 1 (T1), 6 (T2), 12 (T3) months post-immunization. Patients and HC had similar response to individual PnPS. Mean antibody levels to all PnPS but one doubled at T1 compared with T0, with T3 persistence for only 8-7/13 PnPS. Baseline antibody levels was inversely associated with the rate of responders at T1 (T1/T0≥2) to 11/13 PnPS. Few subjects reached protective IgG levels against some serotypes frequently isolated in Italian patients with invasive pneumococcal disease. Antibody response was not influenced by therapy, except the one to PS7F, which was reduced by tumor necrosis factor-α-inhibitors. Vaccination increased also anti-diphtheria IgG. Despite this study substantially confirmed the PCV13 immunogenicity in immunocompromised patients, it also revealed some limitations.
KW - 13-valent pneumococcal conjugate vaccine
KW - Antibody persistence
KW - Immunogenicity
KW - Immunosuppressive therapy
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=85050367427&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050367427&partnerID=8YFLogxK
U2 - 10.1016/j.clim.2018.07.010
DO - 10.1016/j.clim.2018.07.010
M3 - Article
AN - SCOPUS:85050367427
VL - 195
SP - 18
EP - 27
JO - Clinical Immunology
JF - Clinical Immunology
SN - 1521-6616
ER -